1例吉非替尼致Ⅱ级骨髓抑制的病例报告及文献复习  

A case report of a gradeⅡmyelosuppression caused by gefitinib and literature review

作　　者：张楠[1] 张捷 王新[1] 艾超 ZHANG Nan;ZHANG Jie;WANG Xin;AI Chao(Department of Pharmacy,Beijing Tsinghua Changgung Hospital/School of Clinical Medicine,Tsinghua University,Beijing,102218,China)

机构地区：[1]清华大学附属北京清华长庚医院药学部/清华大学临床医学院,北京102218

出　　处：《肿瘤药学》2022年第5期681-684,共4页Anti-Tumor Pharmacy

摘　　要：分析1例EGFR基因突变肺腺癌患者因服用吉非替尼片导致Ⅱ级骨髓抑制的病例,提示临床警惕吉非替尼使用过程中可能出现的骨髓抑制风险,并通过复习相关文献,探讨吉非替尼可能引起的不良反应以及骨髓抑制的治疗方法,为临床用药安全提供参考。A case of gradeⅡmyelosuppression caused by gefitinib in a patient of lung adenocarcinoma with EGFR genetic mutation was analyzed here to remind the clinical vigilance against possible risk of myelosuppression during the administration of gefitinib.Meanwhile,by reviewing relevant literature,we also discussed the possible adverse reactions caused by gefitinib and the treatments for myelosuppression,to provide reference for the safety of clinical medication.

关 键 词：吉非替尼 骨髓抑制 表皮生长因子受体酪氨酸激酶抑制剂 不良反应 

分 类 号：R734.2[医药卫生—肿瘤] R730.6[医药卫生—临床医学]